Remegen Co., Ltd.

Remegen, Ltd.

Xuejing Yao

Jianmin Fang

Jing Jiang

Changjiang Huang

Ling Wang

Qiaoyu Xu

Hui Ye

Hongwen Li

Zhuanglin Li

Xuejing Luan

Guiping Qi

Wenlong Sun

Li Wang

Haohua Jie

Shizhong Zhai

Qianjing Bao

The present disclosure relates to a method for detecting TCEP content in ADC by LC-MS/MS. The ADC samples are derivatized by Ellman reaction, and then the TCEP content is measured by LC-MS/MS. This method can exclude the interference caused by the substances that may react with Ellman in complex ADC samples, which provides with no need for sample pretreatment, and with strong specificity.

Method for detecting TCEP content in ADC by LC-MS/MS

The present invention relates to a bifunctional angiogenesis inhibitor, which has VEGF inhibitory activity and FGF inhibitory activity, and can inhibit VEGF and FGF dual factors-induced or high glucose-induced cell proliferation, cell migration, and/or lumen formation. The present invention also relates to the use of the bifunctional angiogenesis inhibitor in inhibiting retinal angiogenesis, such as diabetic retinopathy, age-related macular degeneration and the like.

Bifunctional angiogenesis inhibitor and use thereof

Disclosed are an anti-HER2 antibody and conjugate of the anti-HER2 antibody and small molecule medicine. Also disclosed are uses of the antibody and conjugate thereof in preparing medicine for treating tumor.

Anti-HER2 antibody and conjugate thereof

Growing community of inventors

Yantai, China

Xuejing Yao